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Background: Natural Killer (NK) cells play an important role in tumor prevention, but once tumors form, the
numbers as well as the cytotoxic functions of NK cells are reduced. IL-15 is a cytokine that increases and activates
NK cells. Here we will examine the anti-tumor role of IL-15 in a spontaneous breast cancer model.
Methods: To achieve this, Polyoma Middle T (MT) mice that form spontaneous breast cancer were crossed with mice
that either overexpress IL-15 (IL-15 transgenic (TG)) or mice that lack IL-15 (IL-15 knockout (KO)). We compared survival
curves and tumor formation in IL-15 KO/MT, MT and IL-15 TG/MT groups. In addition, the phenotype, activation and
contribution of NK cells and CD8 T cells to tumor formation were examined in each of these mouse strains via flow
cytometry, ELISA, adoptive transfer and antibody depletion experiments.
Results: IL-15KO/MT tumors formed and progressed to endpoint more quickly than MT tumors. These tumors
displayed little apoptosis and poor CD8 T cell infiltration. In contrast, IL-15 TG/MT mice had increased survival
and the tumors displayed extensive cell death, high proportions of activated NK cells and a higher infiltration of
CD8 T cells than MT tumors. CD8 T cells in IL-15 TG/MT tumors were capable of secreting IFNγ, possessed markers
of memory, did not display an exhausted phenotype and were frequently NK1.1+. Long-term antibody depletion
studies in IL-15 TG/MT mice revealed that NK1.1+, but not CD8 T cells, were critical for tumor destruction. Lastly,
human NK cells, when exposed to a similar cytokine environment as that found in IL-15TG/MT tumors, were
capable of killing human breast cancer cells.
Conclusions: This study reveals that high levels of IL-15 can promote tumor destruction and reduce metastasis in
breast cancer via effects on NK1.1+ cells. Our results suggest that strategies aimed at increasing NK cell activation may
be effective against solid epithelial cancers.
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Natural Killer (NK) cells were discovered almost 40
years ago due to their ability to kill tumor cells with no
prior sensitization [1]. Since then, extensive knowledge
has been gained about their instrumental role in tumor
immunosurveillance [2]. NK cells are capable of killing
tumor cells via multiple mechanisms. The ability of an
NK cell to kill another cell is controlled by a balance of
activating and inhibitory receptors expressed on their
cell surface that allow the NK cells to sense self versus* Correspondence: ashkara@mcmaster.ca
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unless otherwise stated.damaged cells [3]. Recently, it has been shown that in
addition to preventing tumor formation, NK cells can
eradicate large solid tumors [4] and kill mammary can-
cer stem cells [5]. Unfortunately, in several malignancies,
including breast cancer, NK cell activity as well as ex-
pression of activating receptors, is often suppressed
[6,7]. Tumors promote this down regulation by the se-
cretion of molecules such as TGF β and IL-10 [7-9]. Re-
cent reports suggest that NK cells within the tumor may
actually support tumor growth [10,11]. Alterations in
NK cell activity are reversible, as NK cells rapidly re-
spond to their environment [7,12]. The ability to shift
the NK cell phenotype from inhibition/tumor promotionl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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against cancer.
IL-15 is a cytokine that has effects on both the innate
and the adaptive immune system. IL-15 promotes the
differentiation, proliferation and activation of NK cells
and the formation of a subset of memory CD8 T cells
[13-15]. This has been confirmed in IL-15 TG mice
which have increased activated NK cells and increased
proportions of memory CD8 T cells, whereas IL-15 KO
mice lack NK cells and have decreased CD8 T cells
[16,17]. The ability of IL-15 to promote both NK cell
and CD8 T cell responses has led to interest in IL-15 as
a cancer immunotherapy. Most in vivo studies investi-
gating the effects of IL-15 have used subcutaneous
engrafted or lung metastasis cancer models. For ex-
ample, several studies found that IL-15 TG mice were
resistant to engrafted tumor formation [18,19]. IL-15 has
been administered by several routes and use of each of
these methods has impaired tumor growth or metastasis
[20-25]. The protection observed was either NK cell
and/or CD8 T cell dependent [18-20,22]. While many
treatment strategies have been successful in engrafted
and metastatic models, it is unknown if this will trans-
late into a spontaneous epithelial cancer model where
tumors initiate and grow alongside an intact tolerized
immune system.
In this study, we crossed IL-15 KO and IL-15 TG mice
with a spontaneous breast cancer model (MT) to create
IL-15 KO/MT and IL-15 TG/MT mice. MT mice express
the polyoma MT antigen under the mouse mammary
tumor virus long terminal repeat [26]. In MT mice, multi-
focal adenocarcinomas form and these frequently
metastasize to the lung [26]. The MT model on a C57BL/
6 background is a good model of human breast cancer as
tumor formation is sequential and goes from focal hyper-
plasia to mammary intraepithelial neoplasms to carcinoma
in situ and ends with multiple invasive tumors [27,28]. IL-
15 KO/MT, MT and IL-15 TG/MT were followed for
tumor formation and endpoint. We characterized the im-
mune environment both systemically and intra-tumorally
and determined the relative contribution of NK and CD8
T cells to the protection we observed in IL-15 TG/MT
mice. Lastly, we confirmed that when human NK cells
were exposed to a similar cytokine environment as was
observed in IL-15 TG/MT tumors, they were capable of
killing human breast tumor cells.
Methods
Animal models
Mice were bred and maintained in the McMaster
Central Animal Facility in “clean” rooms with a 12 hour
day/night schedule and standard temperature controls.
Procedures were approved by the McMaster Animal
Research Ethics Board and comply with the guidelinesset out by the CCAC. MMTV-MT mice (Dr. Gendler,
Mayo Clinic, AZ) were crossed to IL-15 KO (Taconic,
Germantown, NY) and IL-15 TG mice (Dr. Caligiuri,
Ohio State University, OH) to generate IL-15 KO/MT
and IL-15 TG/MT mice (C57BL/6 background). C57BL/6
control mice were purchased from Charles River (Quebec,
Canada).
Tumors
In the subcutaneous model, a MTcell line, established from
a spontaneous MMTV-MT tumor (Mayo Clinic, Arizona),
was injected (1 × 105) subcutaneously. Mice were moni-
tored 3 times per week for tumor formation/endpoint. In
the spontaneous model, mice were palpated weekly for
tumor formation and endpoint (tumors >10 × 10 mm). To
examine metastasis, lungs from each group of mice were
harvested at 120 days of age, perfused with 2% paraformal-
dehyde, embedded and sectioned 2 times 100 μM apart.
Haematoxylin and eosin (H&E) stained sections were
scored as positive or negative for the presence of tumor
cells.
Histology/immunohistochemistry
Tumors were excised from multiple mice per group and
embedded in Tissue-Tek® OCT (Sakura) or fixed in 2%
paraformaldehyde. Fixed sections were stained with
H&E (n > 10 per group). Immunohistochemistry was
performed on OCT sections for CD8α (PharMingen-
#550281; 1:50) and CD4 (PharMingen- #550278; 1:50)
using a Rat on Mouse Kit (Biocare Medical- #RT517H).
Colour was developed using an AEC Chromogen sub-
strate solution (Sigma). For quantitation, 5 random fields
of view per section were counted in 5 mice per group
(blinded). A TUNEL assay (ApopTag In Situ Apoptosis
Detection Kit- Millipore) was also performed as per
manufacturer’s instructions on 3 size matched tumors
per group.
Flow cytometry
To generate single cell suspensions, tumors were ex-
cised, digested (3 mg/ml Collagenase A, 0.025 mg/ml
DNase I (Roche) - 45 min., 37°C, with shaking), and fil-
tered sequentially (70 μm, 40 μM). Spleens were also
collected and a single cell suspension was created by
squishing. Red blood cells were removed with ACK lysis
buffer. Cells were incubated with anti-mouse CD16/32
(eBioscience- #14-0161-86) (1 in 100, 15 min, 4°C) and
then stained for markers including: NK1.1, CD69,
NKG2D, NKp46, CD8, CD4, CD3, CD44, PD-1, CD27,
CD62L and IFNγ/Perforin (intracellular flow cytometry
using BD-cytofix/cytoperm) (eBiosciences/BD Biosci-
ences). For flow cytometry analysis of tumors, the first
gate was drawn on singlets followed by CD45+ cells
(leukocytes) to exclude tumor cells. Fluorescence minus
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ments. Samples were run on the BD LSRII or CANTO
flow cytometer and FlowJo (Tree Star, Ashland, OR) was
used for analysis.
T cell stimulation
Cells were isolated from spleens and tumors as de-
scribed above and CD8 T cells were isolated using a
CD8 T cell selection kit (Stem cell- #18753). Purity was
assessed by flow cytometric analysis and was >80% for
tumors and >90% for spleens. 96 well plates were coated
overnight with purified 1 μg/ml anti-CD3 (eBioscience-
#16-0031-82) and 5 μg/ml anti-CD28 (eBioscience- #16-
0281-82) antibodies at 4°C. The next day, plates were
washed and 5 × 105 CD8 T cells/well were added. Super-
natants were collected 48 hours later. In the case of
intracellular flow cytometry, the same process was
followed, but after 12 hours, GolgiStop (BD Biosciences)
was added for 10 hours prior to flow staining.
ELISA/Cytokine analysis
IFNγ (DY485), TNFα (DY410E) and IL-12 p40 (DY499)
ELISAs were performed using Murine DuoSet Kits from
R&D Systems (Minneapolis, MN) as per manufacturer’s
instruction. For IL-18 levels, 3 tumors per group (size
matched) were homogenized and pooled in an equal vol-
ume and sent to Rules Based Medicine (RBM, Austin,
TX) for multi-analyte protein analysis (RodentMAP® ver-
sion 2.0).
NK/Tumor Cell Killing assay
Mouse
NK cells were isolated from the spleens of C57BL/6
mice (PE selection kit Stem cell- #18551 with NK1.1-PE,
2 μg/ml). The MT cell line was labelled with 5-6-
carboxyfluorescein diacetate succinimidyl ester (CFSE, 5
μM) and incubated with the NK cells at various Effector:
Target ratios (1:1, 5:1, 10:1) for 5 hours (MT cells alone =
basal lysis). After 5 hours, 7-amino actinomycin D (7-
AAD, BD Biosciences, 5 μl/tube) was added and flow cy-
tometry was performed to quantify the percentage of
CFSE and 7-AAD positive cells (dead MT cells). Specific
lysis was calculated via the following formula:
% specific lysis ¼ 100  % sample lysis − % basal lysisð Þ
100 − % basal lysis
Human
Lymphocytes were isolated from PBMCs with Ficoll-
Paque Plus (StemCell- #07907) and NK cells were selected
with a human NK cell enrichment kit (StemCell-
#19055, >90% purity of CD56 + CD3- NK cells). The
resultant NK cells were cultured for 16 hours in IL-2
(100 U/ml) or IL-12 (10ng/ml)/IL-15 (20ng/ml)/IL-18(100 ng/ml)(Peprotech). Cells were washed 4X before
being cultured with CFSE (5 μM) labelled MDA-231
(NCI-60 panel) cells at various E:T ratios (1:1, 5:1, 10:1)
for 5 hours (MDA-231 cells alone = basal lysis). Cells
were then stained with CD45-PE (BD Biosciences) anti-
body and immediately before flow cytometry, 7-AAD
(BD, 5 μl/tube) was added to identify dead cells. FMO
controls were included in each experiment. Flow cytom-
etry analysis was performed to determine PE-CFSE +
7AAD+ cells and the above formula was applied.
Antibody depletion
For the subcutaneous model, mice were given 2 injec-
tions, one day apart of anti-NK1.1 (PK136 mouse IgG2,
hybridoma HB191; ATCC) (200 μg/dose) antibody intra-
peritoneally. Two days later, MT cells were injected sub-
cutaneously (and the 3rd dose of NK1.1 antibody was
administered). NK1.1 depleting antibody was delivered
every 3-4 days to maintain the depletion. In the spontan-
eous model, IL-15 TG/MT mice were given 2 doses of
200 μg anti-NK1.1 mouse IgG antibody or 100 μg of
anti-CD8α mouse IgG (clone 2.43; ATCC) intraperitone-
ally one day apart starting at 4 weeks of age. Depletion
was continued every 3-4 days for the NK1.1 and once
per week for the CD8 antibody for the duration of the
experiment. At endpoint, animals were sacrificed and
spleens/tumors were examined for depletion (n ≥ 3). Tu-
mors were fixed (2% paraformaldehyde) and H&E sec-
tions were prepared.
Statistical analysis
Statistics were performed in GraphPad Prism. T tests or
One-way ANOVAs (Bonferonni’s post test) were per-
formed, depending on the number of groups to be com-
pared and error bars represent standard error of the
mean (SEM). Survival curves were analyzed with the
Log Rank test (Mantel-Cox).
Results
Overexpression of IL-15 leads to resistance to subcutaneous
MT tumor formation, while lack of IL-15 leads to faster
tumor growth compared to control mice
To determine if the presence or absence of IL-15 had an
impact on the formation of subcutaneous breast tumors,
C57BL/6, IL-15 KO and IL-15 TG mice were injected with
1 × 105 MT cells subcutaneously and observed for end-
point. Most IL-15 TG mice were resistant to tumor for-
mation (80% survival), whereas IL-15 KO mice proceeded
to endpoint more quickly (n = 5/group) (Figure 1A). To
determine if NK cells contributed to tumor protection,
NK cells were depleted in control mice. NK cell depletion
promoted tumor formation (data not shown) and de-
creased survival (Figure 1B). To further explore the role of
NK cells, we tested whether NK cells were capable of
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of 10:1, we saw 47% specific lysis of MT cells by NK
cells (Figure 1C). Therefore, NK cells can protect from
this engrafted breast tumor model and are capable of
killing MT cells specifically. We next sought to deter-
mine if this would extend to a spontaneous breast
tumor model in which tumors form more similarly to
those in humans [27].
Overexpression of IL-15 leads to destruction of spontaneous
mammary carcinoma
To establish the role of IL-15 in spontaneous breast
tumor formation, MT mice were crossed to IL-15 KOFigure 1 Subcutaneous breast tumor formation in IL-15 TG, IL-15 KO
and C57BL/6 mice with MT cell line. (A) 1 × 106 MT cells were
injected subcutaneously into IL-15 KO, C57BL/6 and IL-15 TG mice
(n = 5/group). IL-15 TG mice were resistant to tumor formation in
comparison to either the IL-15 KO or C57BL/6 mice. (B) Depletion of
NK cells in C57BL/6 mice via NK1.1 antibody led to decreased
survival (n = 5/group). (C) NK cells isolated from the spleen of
C57BL/6 mice (E-Effector) efficiently kill MT tumor cells (T-Target) in a
killing assay (n = 3). *p < 0.05, **p < 0.01.and IL-15 TG mice to create IL-15 TG/MT and IL-15 KO/
MT mice. To confirm that the IL-15 KO and IL-15 TG
phenotype was maintained upon addition of the MT trans-
gene, spleens from 6-8 week old mice were analyzed by
flow cytometry. Both IL-15 KO and IL-15 KO/MT mice
lack NK1.1 + CD3- NK cells and have decreased CD8 T
cells (6% of total lymphocytes)(Figure 2A/B). In addition,
IL-15 TG and IL-15 TG/MT mice both have similar
amounts of NK cells (9% of total lymphocytes) and in-
creased CD8 T cells (21% of total lymphocytes). In control
C57BL/6 and MT mice there were 4-5% NK cells and 12%
CD8 Tcells.
To visualize the effect of IL-15 on tumor formation,
tumors of all sizes were excised from IL-15 KO/MT, MT
and IL-15 TG/MT mice and were sectioned for H&E
staining (Figure 2C). IL-15 KO/MT tumors were solid,
well vascularized tumors with very little cell death. In
contrast, IL-15 TG/MT tumors were mainly necrotic
with very few healthy tumor cells, had increased
lymphocytic infiltration and TUNEL stain revealed cell
death throughout (Figure 2D). The histological differ-
ences were observed in multiple tumors excised at vari-
ous sizes (n > 10/group).
IL-15 affects the speed of tumor formation, the
progression to endpoint and metastasis in a spontaneous
breast tumor model
The extensive histological differences between IL-15
TG/MT and IL-15 KO/MT mice indicated that IL-15
may play a role in tumor formation and progression to
endpoint. In MT mice, multifocal mammary adenocar-
cinomas developed in 100% of mice at a median of 95
days and the median age of endpoint was 153 days
(Figure 3A/B). IL-15 KO/MT tumors formed faster
(median = 78 days) and progressed to endpoint more
quickly than either MT or IL-15 TG/MT tumors (re-
spectively, p < 0.0001, p < 0.01) (Figure 3A/B). IL-15
TG/MT mice had increased survival when compared
to MT mice (p < 0.01) (Figure 3B).
In the MT mouse model, tumors frequently metastasize
to the lung [26]. To examine metastasis in the absence or
overexpression of IL-15, mice from each group were ana-
lyzed for lung tumor metastasis at 120 days of age. While
not statistically significant, it is interesting to note that 29%
of IL-15 TG/MT mice (n = 14), 46 % of MT mice (n = 13)
and 55% of IL-15 KO/MT (n = 11) had detectable metasta-
sis at this time point (Figure 3C).
Tumors in IL-15 TG/MT mice have higher proportions of
activated NK cells
Since IL-15 is known to promote the differentiation, sur-
vival and activation of NK cells, we examined the status
of NK cells within these tumors [13,14,17]. Tumors were
excised, digested and stained for flow cytometry markers
Figure 2 (See legend on next page.)
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Figure 2 Impact of lack of IL-15 or overexpression of IL-15 on lymphocytes in the MT background and on tumor histology. (A & B) Spleens
from 6-8 week old IL-15 KO, IL-15 KO/MT, BL/6, MT, IL-15 TG and IL-15 TG/MT were analyzed by flow cytometry for NK cells (A) and CD8 T
cells (B) (representative of n = 3, IL-15 KO, BL/6 and IL-15 TG, n = 2 IL-15 KO/MT, MT and IL-15 TG/MT). Both IL-15 KO and IL-15 KO/MT mice
have few NK cells and have reduced proportion of CD8 T cells. In contrast, IL-15 TG and IL-15 TG/MT mice both have an equal increase in
NK cells and CD8 T cells proportions. (C) H&E staining of IL-15 KO/MT, MT and IL-15 TG/MT tumors. Representative images from n > 10 per
group (1.6X and 5X). Arrows indicate areas of tumor destruction. (D) TUNEL stain (ApopTag In Situ Apoptosis Detection Kit- Millipore) on
cryosections from representative IL-15 KO/MT, MT and IL-15 TG/MT tumors (n = 3/group) (Apoptosis = dark brown).
Figure 3 Percent tumor free (A), survival curve (B) and percent
with lung metastasis (C) for MT, IL-15 KO/MT and IL-15 TG/MT
mice. Mice were palpated and tumors were measured once per
week to determine date of first palpation or endpoint. (A) The
median age of tumor palpation and number of mice per group
was as follows; MT 95 (n = 30), IL-15 KO/MT 78 (n = 30) and IL-15
TG/MT 93 (n = 36). There is a statistical difference between the IL-
15 KO/MT mice and the MT or IL-15 TG/MT mice (p < .0001). (B)
The median age of endpoint and number of mice per group was
as follows; MT 153 (n = 30), IL-15 KO/MT 136.5 (n = 30) and IL-15
TG/MT 157 (n = 28). In comparison to MT mice IL-15 TG/MT mice
have increased survival (p = .0051), whereas IL-15 KO/MT mice
have decreased survival (p = .002). (C) Percentage of mice with
lung metastasis at 120 days of age (MT n = 13, IL-15 KO/MT n =
11 and IL-15 TG/MT n = 14). *p < 0.05, **p < 0.01.
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NK cells (Figure 4). To analyze leukocyte populations
alone, sample analysis was conducted on CD45+ cells.
The IL-15 TG/MT tumors had a much higher propor-
tion of NK1.1 + CD3- cells than MT tumors (p < 0.01)
(Figure 4A). It has been shown that tumors possess or
secrete several factors that can decrease NK cell activa-
tion [2,9,29]. We found that 80% of NK cells within the
IL-15 TG/MT tumors possessed the early activation
marker CD69, whereas <40% of MT NK cells were
CD69+ (Figure 4B). In IL-15 TG/MT tumors, more NK
cells expressed perforin, a key molecule indicative of
cytotoxicity potential. In addition, a higher percentage of
NK cells in IL-15 TG/MT tumors were in the CD27high
subgroup, which indicates an increased cytotoxicity and
lower threshold of activation (Figure 4B) [30]. Lastly, the
NK cells within IL-15 TG/MT tumors had higher levels
of the activating receptors NKp46 and NKG2D
(Figure 4B).
IL-15 TG/MT tumors possess increased functional CD8 T
cells
IL-15 is capable of stimulating the production of anti-
tumor memory CD8 T cells [15,31]. Therefore, we
wanted to determine if we had altered the T cell environ-
ment within the tumors when we altered the IL-15
levels. CD8α immunohistochemistry on IL-15 KO/MT,
MT and IL-15 TG/MT tumor sections revealed that
there were higher numbers of CD8 T cells within IL-15
TG/MT tumors in comparison to either IL-15 KO/MT
or MT tumors (p < 0.001 for both) (Figure 5A/B). In
contrast, there were approximately equal numbers of
CD4 T cells in all of the tumor groups (Figure 5C). Re-
searchers have found that a high CD8/CD4 ratio is a
positive prognostic factor in tumors [32]. Using flow cy-
tometry, the CD8 to CD4 ratio was found to be much
higher for IL-15 TG/MT (mean = 5.63) than IL-15 KO/
MT tumors (mean = 0.43) (Figure 5D).
To phenotype CD8 T cells in IL-15 TG/MT mice, we ex-
amined CD44 and CD62L expression. CD8 T cells in the
majority of IL-15 TG/MT tumors possessed a CD44 +
CD62Lhigh central memory population (>2 times higher
than CD8 T cells of MT mice) (Figure 5E). The presence of
CD8 T cells in the tumor is generally a positive prognostic
factor, but CD8 T cells within tumors have been reported
Figure 4 A comparison of NK cell phenotype in IL-15 TG/MT and MT tumors. Tumors from MT, IL-15 KO/MT and IL-15 TG/MT mice were digested
and stained for flow cytometry (only one tumor taken from each mouse). (A) Of CD45+ cells in the tumor, there was a higher proportion of
NK1.1+ cells in the IL-15 TG/MT tumors than in the MT or IL-15 KO/MT tumors (n = 10- IL-15 KO/MT, 8- MT or IL-15 TG/MT). (B) In the IL-15 TG/MT
tumors, the majority of the NK cells possess the early activation marker CD69. In addition, a higher percentage of NK cells in IL-15 TG/MT tumors
possess CD27, a marker of highly cytotoxic NK cells. Lastly, a higher percent of the NK cells in IL-15 TG/MT tumors possess the activation markers
NKp46 and NKG2D, as well as perforin (n = 3 to 9). *p < 0.05.
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To test this, CD8 T cells were isolated from the
spleens or tumors of IL-15 KO/MT, MT and IL-15
TG/MT mice, and stimulated non-specifically for 48
hours. CD8 T cells from IL-15 TG/MT spleens and tu-
mors both produced higher levels of IFNγ and TNFα
than those from MT mice (Figure 5F, Additional file 1:
Figure S1C). IL-15 KO/MT spleen or tumor CD8 Tcells produced little to no IFNγ (data not shown). We
further examined the CD8 T cells via flow cytometry
to determine which CD8 T cell populations were pro-
ducing IFNγ (Figure 5G, Additional file 1: Figure S1).
We isolated CD8 T cells and performed non-specific
stimulation in the presence of GolgiStop (BD) to pre-
vent protein secretion. A higher percentage of CD8 T
cells from IL-15 TG/MT tumors produced IFNγ and
Figure 5 (See legend on next page.)
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Figure 5 CD8 T cell phenotype in IL-15 TG/MT, IL-15 KO/MT and MT tumors. (A) CD8 T cell immunohistochemistry on representative IL-15 KO/MT, MT
and IL-15 TG/MT tumors. Levels of CD8 T cells were highest in IL-15 TG/MT tumors and lowest in IL-15 KO/MT mice (brown staining = CD8+, 20X) (B)
Quantitation of CD8 T cells in tumors (n = 5 mice/group) (C) Quantitation of CD4 T cells in tumors assessed by immunohistochemistry (n = 5 mice/
group) (D) Tumors from MT, IL-15 KO/MT and IL-15 TG/MT mice were digested and stained for flow cytometry. The CD8+/CD4+ T cell ratio is altered
drastically in the presence or absence of IL-15 (n = 5 mice/group). (E) CD3 + CD8+ cells from tumors of IL-15 TG/MT mice have a higher
percentage of CD62L + CD44+ central memory T cells (Representative of n = 3/group) (F/G) CD8 T cells were isolated by positive selection
from tumors of mice and stimulated non-specifically. (F) After 48 hours, supernatant IFNγ/TNFα levels were highest in CD8 T cells from IL-15
TG/MT mice (n = 2/group) (Representative of 3 experiments). (G) In another set of experiments, after 12 hours of stimulation, Golgi Stop was
added to determine via flow cytometry which cells were capable of producing IFNγ. A high proportion of IL-15 TG/MT CD8 + CD3+ cells
produce IFNγ in comparison to MT CD8 T cells (n = 3/group). (H) Fewer CD8 + CD3+ T cells in IL-15 TG/MT mice express the exhaustion marker
PD-1 (n = 3/group). *p < 0.05, p < 0.01.
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cells with central memory phenotype markers (CD44
+ CD62L+)(Figure 5G, Additional file 1: Figure S1A).
After selecting the CD8 T cells that were capable of
producing IFNγ, we determined that these cells were
all CD44+, and in the case of IL-15 TG/MT, many
were also CD62L+ (Additional file 1: Figure S1B).
Therefore, IL-15 TG/MT mice have higher numbers
of polyfunctional and central memory CD8 T cells. To
ascertain if the CD8 T cells were exhausted, we exam-
ined them for the marker programmed death (PD)-1.
This marker is increased on exhausted CD8 T cells in
a variety of models [35]. PD-1 was high on intra-
tumoral IL-15 KO/MT and MT CD8 T cells, but low
on IL-15 TG/MT CD8 T cells (Figure 5H).
Tumors in IL-15 TG/MT mice contain significant numbers
of CD3 + CD8 + NK1.1+ cells
Phenotyping the CD8 T cells from these mouse strains
revealed a large proportion of IL-15 TG/MT tumor CD8
T cells that also expressed NK1.1 (Additional file 1:
Figure S2A). These NK1.1 + CD8 T cells were absent in
IL-15 KO/MT tumors and much lower in MT tumors
(Additional file 1: Figure S2A). To determine if these
cells produced high levels of IFNγ, we isolated NK1.1+
cells from IL-15 TG/MT tumors and performed non-
specific stimulation (CD3/28) in the presence of protein
secretion inhibitors. 11-13% of CD3 + CD8+ NK1.1+ T
cells produced IFNγ, a similar percent to that seen for
total CD8 T cells that produced IFNγ (Additional file 1:
Figure S2B, 5G). Therefore, in our model, these cells
were capable of producing IFNγ, but were not the only
CD8 T cells doing so.
Cells expressing NK1.1 are responsible for tumor
destruction in IL-15 TG/MT mice
To determine which cell type(s) were responsible for
anti-tumor responses in IL-15 TG/MT mice, we per-
formed long term antibody depletion experiments with
anti-NK1.1 or anti-CD8α antibody in IL-15 TG/MT
mice. NK1.1 depletion efficiently depleted NK1.1+ cells
within the spleen and tumor (Additional file 1: Figure S3A).IL-15 TG/MT mice that were depleted of NK1.1+ cells
formed tumors faster and proceeded to endpoint more
quickly than IL-15 TG/MT mice (p < 0.001, 0.0001, re-
spectively) (Figure 6A). In fact, tumor formation closely
followed what was observed in IL-15 KO/MT mice. In
addition, histological analysis revealed that the tumor de-
struction in IL-15 TG/MT mice was absent when these
NK1.1+ cells were absent (Figure 6C). The anti-CD8α anti-
body removed CD8 expressing cells from the spleen of IL-
15 TG/MT mice, but only partially from the tumor (at
least by 2/3 ie. 18% to 6%)(Additional file 1: Figure S3B).
The majority of the CD3 + CD8+ T cells that were left
in the depleted tumor were NK1.1+ (Additional file 1:
Figure S3C). There were no statistically significant
differences between the IL-15 TG/MT and the IL-15
TG/MT CD8 depleted mice (Figure 6B). Lastly, the tu-
mors that formed in IL-15 TG/MT CD8 depleted mice
had similar tumor destruction to that seen in normal
IL-15 TG/MT mice (Figure 6C). Therefore, NK1.1+ cells
play a major role in the tumor destruction and extension
of survival in IL-15 TG/MT mice, whereas CD8 T cells,
although activated phenotypically, play less of a role.
Adoptive transfer of CD8 T cells from IL-15 TG/MT mice
does not lead to protection from tumor challenge
To further examine the impact of CD8 T cells from IL-
15 TG/MT mice on tumor formation, we performed
CD8 T cell adoptive transfers. C57BL/6 recipient mice
were treated with cyclophosphamide to induce lympho-
penia. 24 hours later CD8 T cells were isolated from the
spleens/tumors of MT, IL-15 TG/MT and IL-15 TG
mice, labelled with CFSE (5 × 106 spleen, 1 × 106 tumor)
and injected IV. 24 hours after transfer, mice were chal-
lenged with a sub-cutaneous dose of fresh primary MT
tumors from which immune cells had been removed.
Mice were followed for tumor formation and endpoint.
8 days after challenge, several mice were sacrificed to en-
sure that the adoptive transfer was successful (4-8% of
total CD8 T cells were CFSE positive - data not shown).
There were no statistically significant differences in
tumor formation or endpoint between control mice that
received no CD8 T cells and mice that received CD8 T
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IL-15 TG/MT tumors (Additional file 1: Figure S4).
The effect of cytokines on the ability of human NK cells
to kill a human breast cancer cell line
IL-15 overexpression in MT breast tumors created an
environment where several cytokines that affect NK cell
activation and proliferation were altered. We examined
the expression of these cytokines in IL-15 TG/MT tu-
mors versus MT or IL-15 KO/MT tumors and found
that in addition to IL-15, both IL-12 and IL-18 were in-
creased within IL-15 TG/MT tumors (Figure 7A/B). To
determine if exposure to these 3 cytokines simultan-
eously would affect the ability of NK cells to kill breast
tumor cells, we isolated NK cells from human PBMCs
and stimulated them in an IL-15/IL-12/IL-18 rich envir-
onment for 16 hours. We then co-incubated them with
a CFSE labelled MDA-231 human breast cancer cell line
at various E:T ratios for 5 hours to determine their kill-
ing potential. The gating strategy used can be seen in
Figure 7C and included exclusion of CD45+ NK cells,
selection of CFSE+ tumor cells and finally the percent of
CFSE+ tumor cells that were dead (7AAD+). MT cells
alone were included as the level of basal MT cell death.
In contrast to NK cells cultured in IL-2 alone, NK cells
cultured in IL-15/IL-12/IL-18 were highly cytotoxic to-
ward this breast cancer cell line and at E:T ratios of 10:1
reached specific lysis levels of 52% (Figure 7C/D).
Discussion
While IL-15 has been under investigation as a cancer
immunotherapeutic for the last decade, investigation has
focused on tumor models that do not closely mimic
spontaneous tumor formation in humans. It is known
that injecting tumor cell lines subcutaneously or intra-
venously is a useful, but rather artificial system in which
it is easier to develop immune responses to the tumor.
In addition, there is a lack of studies that have examined
the impact of IL-15 on solid epithelial tumors such as
breast cancer. To examine the role of IL-15 in a more
relevant model we utilized an immunologically tolerant
mouse model of spontaneous mammary tumor forma-
tion (MT) and examined tumor formation in the ab-
sence of IL-15 (IL-15 KO/MT) or with IL-15
overexpression (IL-15 TG/MT). Overall, IL-15 TG/MT
mice had increased survival when compared to either
MT or IL-15 KO/MT mice. In contrast IL-15 KO/MT
mice had faster tumor formation and decreased survival
when compared to MT or IL-15 TG/MT mice. These re-
sults are similar to the anti-tumor effects of IL-15 that
have been observed in other engrafted and metastatic
models of melanoma and colon cancer, but it is one of
the first reports of this in a spontaneous model of breast
cancer [18,19,21].IL-15TG/MT mice formed tumors, but these tumors
had a very different phenotype than IL-15 KO/MT or
MT tumors. This included large areas of cell death, a
higher proportion of NK cells as well as increased CD8
T cell infiltration. Increased CD8 T cells or NK cells
within the tumor is a positive prognostic factor in many
human and mouse tumor types [32,36,37]. In many cases
though, NK cells within the tumor express inhibitory re-
ceptors instead of activating receptors and have low
cytotoxicity [7,38]. To examine NK cell phenotype, we
identified NK cells using flow cytometry as NK1.1 +
CD3- cells. NK1.1 is commonly used as a marker for NK
cells in C57BL/6 mice. It is a member of the NKRP1 re-
ceptor family and while it is thought to be an activating
receptor its’ ligand is unknown [39-41]. The NK cells
within IL-15 TG/MT tumors possessed higher levels of
both activating receptors (NKG2D, NKp46) and other
markers of activation (CD69). Recently, ligands for
NKG2D and NKp46 were found to be expressed on hu-
man primary breast tumors and breast tumor cell lines
[9]. In addition, blockade of either NKp46 or NKG2D
decreased the ability of NK cells to kill breast tumor
cells that expressed ligands to these receptors [9]. We
also found that there was a higher percentage of
CD27high NK cells in IL-15 TG/MT tumors than in MT
tumors. CD27 expression, in addition to CD11b expres-
sion, has been used to define mature mouse NK cells
into subsets [30,42]. In progression from less mature to
more mature: CD27lowCD11blow to CD27highCD11blow
to CD27highCD11bhigh to CD27lowCD11bhigh [42]. Im-
portantly, CD27high NK cells were found to have a
higher degree of effector function, including cytotoxicity
and cytokine production [30]. More recently it was
found that CD27 on human NK cells could also be used
to define NK cell subsets [43,44]. In contrast to what has
been found with mouse NK cells, human CD27+ NK
cells have been associated with low cytotoxic activity
and high ability to secrete cytokines [43,44]. Overall, NK
cells found within IL-15 TG/MT tumors are likely more
capable of killing breast tumor cells than those found in
MT tumors.
We observed increased CD8 T cells within IL-15 TG/
MT tumors, but CD8 T cells within the tumor are not
always functional as they can be anergic and/or
exhausted [33,35]. While IL-15 KO/MT tumor CD8 T
cells had high levels of exhaustion markers (PD-1) and
lacked IFNγ production, IL-15 TG/MT CD8 T cells had
very low levels of PD-1 and produced large amounts of
IFNγ. This is in contrast to another report that found
that treatment with IL-15 in a metastatic model of colon
carcinoma led to increased PD-1 expression on CD8 T
cells in the spleen [45]. It is likely that the short term ad-
ministration of IL-15 or the model system used
accounted for the discrepancies in our observations. In
Figure 6 (See legend on next page.)
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Figure 6 The effect of NK1.1 and CD8α depletion on tumor formation. (A-B) IL-15 TG/MT mice were depleted with anti-NK1.1 (n = 6) (A) or
anti-CD8α (n = 5) (B) antibody long term starting at 4 weeks of age. (A) In comparison to the tumor formation and survival curves for IL-15
TG/MT mice (n = 36 for percent tumor free, n = 28 for survival), NK1.1 depleted IL-15 TG/MT mouse tumors formed and progressed to endpoint
more quickly. IL-15 TG/MT NK1.1 depleted mice were not different from IL-15 KO/MT tumor mice (n = 30). (B) In comparison to the tumor
formation and survival curves for IL-15 TG/MT mice, CD8 depleted IL-15 TG/MT mouse tumors formed and progressed to endpoint at a similar
rate. (C) Tumors that formed in IL-15 TG/MT NK1.1 depleted mice did not show the extensive destruction seen in normal IL-15 TG/MT tumors
and in IL-15 TG/MT CD8 depleted mice. Arrows indicate areas of tumor destruction. **p < 0.01, ***p < 0.001.
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TG/MT tumors were CD44+ and CD62Lhigh, which are
markers of central memory CD8 T cells. Central mem-
ory CD8 T cells are thought to be extremely effective in
anti-tumor defence [31,46]. We also observed a high
proportion of unique NK1.1+ CD8 T cells in IL-15 TG/
MT tumors. This cell type has been previously identified
as highly cytotoxic (high perforin/granzyme level) and
able to produce large amounts of IFNγ [47,48]. In our
model, while some of these cells produce IFNγ, they
were not the major source. While we have not examined
this here, it is interesting to speculate about whether
these unique CD8 T cells developed in the tumor or mi-
grated to the tumor from elsewhere. We do know that a
low percentage of these cells can be found in IL-15 TG
mice in other organs such as the spleen (data not
shown), so they are not completely unique to the tumor
environment. The ability of IL-15 to induce expression
of other NK cell markers such as CD56 in human CD8
T cells has also been reported in a variety of models
[49,50]. Thus, this effect does not appear to be limited
to our mouse models or to one type of NK cell receptor.
In previous studies involving IL-15, protective effects
were found to be NK cell or CD8 T cell dependent
[18,19,22]. In IL-15 TG/MT mice, NK1.1 positive (in-
cludes NK cells, NKT cells, NK1.1+ CD8 T cells) but not
CD8 positive cells were the most important cells for in-
creased survival and tumor destruction. The CD8 deple-
tion was substantial but not complete in the tumor and
the majority of CD8 T cells that remained in the tumor
were NK1.1+, indicating that this cell type was resistant
to depletion via this method. It has previously been
reported that these cells may be resistant to activation-
induced cell death and this may contribute to the ineffi-
cient depletion [48]. Since CD3 + CD8 + NK1.1+ cells
were removed by the NK1.1 depletion, we cannot rule
out a role for this cell type in the tumor destruction of
IL-15 TG/MT mice. The lack of contribution of CD8 T
cells to increased survival was surprising due to the fact
that they existed in such high numbers and were of the
correct phenotype to fight cancer. To confirm this data,
we performed a CD8 T cell adoptive transfer experiment.
Despite the fact that CFSE labelled CD8 T cells were
present in the spleen and tumor at endpoint (data not
shown), there was no impact on survival from transferof either IL-15 TG/MT, MT or IL-15 TG splenic CD8 T
cells or IL-15 TG/MT tumor CD8 T cells after a sub-
cutaneous primary MT tumor injection. It is possible
that either this aggressive tumor formed too fast for the
transferred CD8 T cells to have an impact or that the
tumor rapidly lost MHC I expression to compensate for
the presence of tumor specific CD8 T cells. Also, MT
tumor formation has been found to be slightly different
each time and different tumors may express different
tumor antigens, some even lose expression of MT itself
[51]. Thus, it is possible that despite taking MT tumor
cells to inject from multiple mice and CD8 T cells from
multiple mice and pooling them, they may still not have
been specific for that tumor. In terms of MHC I loss, a
similar phenomenon may be occurring in the spontan-
eous model. It is also possible that IL-15 overexpression
may induce non-specific proliferation of CD8 T cells,
not tumor specific responses [52]. This data indicates
that overexpression of IL-15 can generate an anti-
tumoral NK cell response that is effective at extending
survival in the MT model.
Another promising finding revealed in this model was
that overexpression of IL-15 appears to delay the forma-
tion of lung metastases. This observation, in a spontan-
eous model of breast tumor metastasis, strongly
indicates that IL-15 has potential therapeutically to pre-
vent metastasis. Previously, this has only been examined
in injected models of metastasis. This may be very useful
in a clinical setting in which metastasis is frequent and
leads to significant increases in mortality.
Conclusions
IL-15 is a promising new cancer therapeutic that is well
tolerated in primate models [53]. It appears to be super-
ior to IL-2 as it has lower toxicity, does not increase T
regulatory cells and induces higher levels of NK cell and
CD8 T cell effector responses [53,54]. Based on the success
of IL-15 in animal models, the first clinical trials have
begun (NCT01727076, NCT01021059, NCT01572593) in
multiple tumor types including melanoma, renal cell car-
cinoma and non-small cell lung carcinoma patients. Re-
cently, there has been renewed interest in NK cells as a
target to activate in the fight against breast cancer. It has
been shown that human breast cancer cells express activat-
ing ligands as well as death-inducing receptors- both of
Figure 7 (See legend on next page.)
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Figure 7 Cytokines in IL-15 TG/MT tumors and their effects on the ability of human NK cells to kill human breast cancer cells. (A & B) IL-12
and IL-18 are increased in IL-15 TG/MT tumors. (A) IL-12 ELISAs were performed on tumor homogenates from 6 size matched tumors per
group. (B) 3 tumors from different mice in each tumor group were pooled (size matched between groups) and assayed for IL-18 cytokine
levels via multianalyte protein analysis. (C & D) NK cells isolated from human PBMCs were cultured in IL-2 or IL-15/IL-12/IL-18 for 16 hours
before being incubated with CFSE labelled MDA-231 cells for 5 hours in a killing assay. In the demonstration of the gating strategy in C)
CD45+ NK cells were first removed from the analysis and then CFSE+ MT cells were selected. 7AAD was used to determine the percentage
of the CFSE+ MT cells that were dead. Results at an E:T ratio of 1:10 are displayed (E:T = NKcell:MDA-231). MT alone is included to show
spontaneous death levels which were used in the calculation of D. (D) Percent specific lysis of MDA-231 in the killing assay at various E:T
ratios. Representative of 2 experiments. *p < 0.05.
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[9,55]. In fact, expression of NKG2D ligands in human
breast cancer was associated with a significant beneficial
outcome [56]. It has also been established that NK cells are
capable of eradicating a solid epithelial cancer (fibrosar-
coma) and that they may also be able to target breast can-
cer stem-cell like cells [4,5]. Here, we found that when
human NK cells were exposed to a similar cytokine envir-
onment to that found in IL-15 overexpressed MT tumors,
they were highly capable of killing a triple negative breast
cancer cell line. Other studies have reported that NK cells
grown in IL-15, IL-12 and IL-18 are thought to display long
term effector functions and may be memory-like NK cells
[57,58]. These studies, along with our data, lends credence
to the idea that stimulating innate immune cells such as
NK cells can be effective clinically against breast cancer pri-
mary tumors and metastasis.Additional file
Additional file 1: Figure S1. IFNγ production by CD8 T cells in the
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starting at 4 weeks of age (representative flow plots from n = 3 in each).
Figure S4. Adoptive transfer of CD8 T cells from IL-15 TG/MT, MT or
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